• 中文版
  • Home
  • About Us
    • Contract Research Organization
    • Contract Development and Manufacturing Organization
    • Accolades
    • Publications
  • Services Overview
  • Discovery Chemistry
    • Synthetic Chemistry
    • Medicinal Chemistry
    • Library Chemistry
    • Peptide Chemistry
    • Fragment Based Screening
    • Computer Aided Drug Design
    • Analytical Services
    • Protein Structure
  • Biology & Pharmacology
    • Oncology
    • Pathology Core Facility
    • Immunology
    • Tumor Immunology
    • Neuroscience
    • Cell Biology
    • In Vitro Biology
      • Kinases
      • Epigenetics
      • GPCR, NR, Ion-channel, Transporter
      • Ubiquitin & PROTAC
      • KRAS
      • COVID-19
      • Radiometric
      • Customized assay development
      • High throughput screening
      • MOA Study
    • Metabolic & Cardiovascular Diseases
  • DMPK / Exploratory Toxicology
    • DMPK / Exploratory Toxicology
    • Biomarkers, Preclinical & Clinical Sample Bioanalysis
    • Large molecule PK/BA services
  • Biologics Discovery
    • Antibody Discovery
    • Protein Science
    • Biologics Analytical Services
    • B Cell Cloning
  • Biologics CMC
    • Stable Cell Line Development
    • Process Development
    • Formulation Development
    • Aseptic Filling and Freeze-drying
    • Drug Developability / Manufacturability study
    • Final Container Extractables & Leachables Study
    • Analytical Development and Testing
    • GMP Production
  • Small Molecule CMC
    • Process R&D Services
    • Process Safety
    • Analytical Development
    • Pre-Formulation Development
    • Formulation Development
    • ICH Stability Studies
    • CMC CTD Support
    • Manufacturing
  • Blog
  • Careers
  • News & Events
    • Webinars
  • Contact Us
  • Download Center

Call us today! +86 21 5132 0088

contact@chempartner.com
中文版
Shanghai ChemPartner Shanghai ChemPartner Shanghai ChemPartnerShanghai ChemPartner
  • Home
  • About Us
    • About ChemPartner
    • CRO
    • CDMO
    • Accolades
    • Publications
  • Services
    • Discovery Chemistry
      • Synthetic Chemistry
      • Medicinal Chemistry
      • Library Chemistry
      • Peptide Chemistry
      • Fragment Based Screening
      • Computer Aided Drug Design
      • Analytical Services
      • Protein Structure
    • Biology & Pharmacology
      • Oncology
      • Pathology Core Facility
      • Immunology
      • Tumor Immunology
      • Cell Biology
      • In Vitro Biology
      • Neuroscience
      • Metabolic & Cardiovascular Diseases
      • Epigenetics
    • DMPK / Exploratory Toxicology
      • DMPK / Exploratory Toxicology
      • Biomarkers, Preclinical & Clinical Sample Bioanalysis
      • Large molecule PK/BA services
    • Biologics Discovery
      • Antibody Discovery
      • Protein Science
      • Biologics Analytical Services
      • B Cell Cloning
    • Biologics CMC
      • Stable Cell Line Development
      • Process Development
      • Formulation Development
      • Aseptic Filling and Freeze-drying
      • Drug Developability / Manufacturability study
      • Final Container Extractables & Leachables Study
      • Analytical Development and Testing
      • GMP Production
    • Small Molecule CMC
      • Process R&D Services
      • Process Safety
      • Analytical Development
      • Pre-Formulation Development
      • Formulation Development
      • ICH Stability Studies
      • CMC CTD Support
      • Manufacturing
  • Blog
  • Careers
  • News & Events
    • Webinars
  • Contact Us
  • Download Center

COVID-19

Home Biology & Pharmacology In Vitro Biology COVID-19

COVID-19

The coronavirus SARS-CoV-2 (often referenced as COVID-19) is an RNA virus with much higher mutation rates than a DNA virus. Therefore, in the battle against the COVID-19 epidemic, in addition to quarantine and vaccine therapy development, a deeper understanding of SARS-CoV-2 and the acceleration of antiviral drugs development are an urgent need.

SARS-CoV-2 Model and Genome

Currently, ChemPartne’s in vitro biology team has conducted in-depth research on the targets of the SARS-CoV-2 that can be used for drug discovery and has progressively developed the corresponding drug screening assays. Our team has collaborated with domestic China as well as global companies and is involved in a number of SARS-CoV-2 projects to facilitate new anti-coronavirus drug discovery.

Papain-like proteinase (PLpro) is the protease mainly responsible for cleaving the N-terminus of the replicase polyprotein to produce three non-structural proteins (NSP1, NSP2, NSP3) and plays a key role in virus replication. As an indispensable enzyme in virus replication, PLpro is a popular drug target for coronavirus. The SARS-CoV-2 and MERS-CoV PLpro enzymatic assays, which are used for new drug discovery, have been established.

SARS-CoV-2 PLpro Enzymatic Assay Development

MERS-CoV PLpro Enzymatic Assay Development

3C-like main proteinase Mpro (3CLpro) is the first mature protease formed by self-cleavage from replicase polyprotein. It is mainly responsible for cleaving replicase polyprotein to produce non-structural proteins from NSP4 to NSP16, which are vital in viral replications. Further studies on the structure and activity of 3CLpro show that it is a potential drug target for coronavirus. Thus, ChemPartner’s in vitro biology team has established the 3CLpro enzymatic assay of SARS-CoV-2 as well.

(SARS-CoV-2 3CLpro enzymatic assay development)

For other SARS-CoV-2 drug targets such as RdRp, Endoribonuclease, etc., the corresponding assay development is underway, which will further contribute to accelerate the SARS-CoV-2 drug discovery process.

  • Service Overview
  • Discovery Chemistry
    • Synthetic Chemistry
    • Medicinal Chemistry
    • Library Chemistry
    • Peptide Chemistry
    • Fragment Based Screening
    • Computer Aided Drug Design
    • Analytical Services
    • Protein Structure
  • Biology & Pharmacology
    • Oncology
      • OncoCP Database
    • Pathology Core Facility
      • Histopathology
      • Molecular Pathology
    • Immunology
      • Primary immune cell assays
      • Immune cell line assays
      • Autoimmune disease models
      • In vivo PD models
      • Immune profiling for MOA
    • Tumor Immunology
    • Neuroscience
      • Volume Discount Fast services for Neuroscience
      • Behavioral Pharmacology
      • In vivo Pain Models
      • Non-Human Primate Cognition
      • In Vitro Electrophysiology
    • Cell Biology
      • Target Validation
      • Cell-based Assays
      • Cancer Cell Line Panel Screen
      • Biomarker Analysis
    • In Vitro Biology
      • Kinases
      • Epigenetics
      • GPCR, NR, Ion-channel, Transporter
      • Ubiquitin & PROTAC
      • KRAS
      • COVID-19
      • Radiometric
      • Customized assay development
      • High throughput screening
      • MOA Study
    • Metabolic & Cardiovascular Diseases
  • DMPK / Exploratory Toxicology
    • DMPK / Exploratory Toxicology
      • In vitro ADME
      • Pharmacokinetics
      • Exploratory Toxicology
      • Bioanalysis
      • Regulatory filing
    • Biomarkers, Preclinical & Clinical Sample Bioanalysis
    • Large molecule PK/BA services
      • Monoclonal Antibodies
      • Antibody Drug Conjugates
      • Bispecific Antibodies
      • Proteins & Peptides
      • Immunogenicity
  • Biologics Discovery
    • Antibody Discovery
      • Hybridoma
      • Antibody Engineering
      • Phage Display
      • Antibody-Drug Conjugate
    • Protein Science
    • Biologics Analytical Services
      • mAb Release Tests and Extended Characterization
      • Antibody-Drug Conjugate(ADC) Analysis
      • Therapeutic Protein Characterization
      • Biomolecular Interaction Analysis
    • B Cell Cloning
  • Biologics CMC
    • Stable Cell Line Development
    • Process Development
    • Formulation Development
    • Aseptic Filling and Freeze-drying
    • Drug Developability / Manufacturability study
    • Final Container Extractables & Leachables Study
    • Analytical Development and Testing
    • GMP Production
  • Small Molecule CMC
    • Process R&D Services
    • Process Safety
    • Analytical Development
    • Pre-Formulation Development
    • Formulation Development
    • ICH Stability Studies
    • CMC CTD Support
    • Manufacturing

Give us a Message

You can leave us a message by quick contact box and we'll get back to you, asap. Thanks!

Send Message

Logo

ChemPartner is a leading research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry.

Get started today.

Contact Us
  • Shanghai ChemPartner Co., Ltd.
  • 1F & 3F, Block A, 2829 JinKe Road, Zhangjiang Hi-Tech Park, PuDong New Area, Shanghai China, 201203
  • +86 21 5132 0088
  • contact@chempartner.com

© 2021 — Shanghai ChemPartner Co., Ltd. All Rights Reserved  About Us  Careers  Contact Us  Privacy Policy  Sitemap

  • Home
  • Contact
  • Buy Highend